Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Therapies for Down Syndrome Regression Disorder

A legfontosabb adatok

Ki végzi
University of Colorado, Denver
Hol
Aurora és Los Angeles (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
66 fő vett részt
Kezdés
2023. jún. 29.
Befejezés
2026. máj. 28.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • Lorazepam
  • Intravenous immunoglobulin (IVIG)
  • Tofacitinib
A regiszteradat frissítve
2026. szeptember 3.

Ki vehet részt

Életkor
8 év – 30 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 41 feltétel megnézéseKevesebb

Ki vehet részt

  • Individuals with DS between the ages of 8 and 30 years, inclusive. DS is broadly defined to include complete trisomy 21, Robertsonian translocation trisomy 21, partial trisomy 21 (segmental duplication), and mosaic trisomy 21
  • Diagnosis of possible or probable DSRD per 2022 consensus guidelines
  • Must agree to random treatment assignment
  • Must agree to complete a washout of any medications intended to treat symptoms of DSRD or that may interfere with study interventions
  • Must be able to present with a study partner or legal guardian at all study visits

Ki nem vehet részt

  • Moyamoya syndrome or stroke (active or prior)
  • IgA deficiency with antibodies against IgA
  • Use of electroconvulsive therapy, lorazepam, or a JAK inhibitor within the last 4 weeks
  • Use of immunosuppressant drugs (e.g., prednisone, mycophenolate mofetil, azathioprine) within the last 8 weeks
  • Use of strong CP3A4 inhibitors or inducers (e.g., ketoconazole, rifampin) within the last 4 weeks
  • Use of moderate CP3A4 inhibitors with a strong CYP2C19 inhibitor (e.g., fluconazole) within the last 4 weeks
  • Use of moderate CYP2C9 inhibitors (e.g., valproic acid) within the last 4 weeks
  • Use of strong CYP1A2 inducers (e.g., phenobarbital) or moderate CYP1A2 inhibitors (e.g., fluvoxamine) within the last 4 weeks
  • Any prior use of methotrexate, cyclophosphamide, or other chemotherapeutics
  • Any prior solid organ transplant
  • Any prior neurosurgical intervention
  • Any subject who has received blood or plasma products ≤ 30 days prior to first Baseline visit
  • Known allergies, hypersensitivity, or intolerance to lorazepam, IVIG, or tofacitinib
  • Participants may be excluded for other unforeseen reasons or confounding reasons for DSRD symptoms at the study doctor's discretion; Co-occurring Conditions
  • Any co-occurring genetic disorder
  • Active symptomatic cardiac disease
  • Clinically significant chronic or active viral infection, including but not limited to HIV, hepatitis, CMV, EBV, HSV or untreated tuberculosis
  • Untreated chronic or active bacterial infection
  • History of disseminated herpes zoster, disseminated herpes simplex, or recurrent localized dermatomal herpes zoster
  • History of malignancy (solid tumor or leukemia)
  • History of acute narrow-angle glaucoma
  • History of venous or arterial thrombosis
  • Pathogenic neuronal autoantibody positivity against established causes of autoimmune encephalopathy in CSF
  • Any subject with a history of anaphylaxis or a severe systemic response to blood or plasma-derived products; Medications or Interventions
  • Baseline abnormal renal function indicative of moderate or severe renal disease by eGFR <=45
  • General
  • Weight less than 40 kg
  • Pregnant or breast feeding
  • Past or current tobacco smoking
  • Poor venous access not allowing repeated blood tests or non-compliance with venipuncture requirements
  • Untreated hypothyroidism or hyperthyroidism
  • Any vaccination planned during the study or within the last 6 weeks
  • Use of IVIG within the last 8 weeks
  • Use of rituximab within the past 6 months, unless B cell levels have recovered and are above 50 cells/uL
  • Use of other immunosuppressant biologics (e.g., adalimumab, etanercept) within the past 6 months
  • Use of certain mood stabilizers or anticonvulsants (e.g., clonazepam, lithium, oxcarbazepine) within the last 4 weeks

Helyszínek itt: Egyesült Államok

  • Children's Hospital ColoradoAurora, Egyesült Államok
  • Children's Hospital Los AngelesLos Angeles, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the neuropsychiatric condition known as Down Syndrome Regression Disorder (DSRD). A DSRD diagnosis often includes a sub-acute onset of catatonia, mutism, depersonalization, loss of ability to perform activities of daily living, hallucinations, delusions, and aggression and is most commonly observed in adolescents and young adults.

A teljes eredeti leírásKevesebb

The study evaluates the safety and efficacy of three currently prescribed therapies: lorazepam, intravenous immunoglobulin (IVIG) and tofacitinib.

A vizsgálat 3 csoportja

  • LorazepamA vizsgált kezelés

    Participants will receive lorazepam as an oral pill three times daily for 12 weeks as well as titration doses for an additional 4 weeks (approximately).

  • Intravenous immunoglobulin (IVIG)A vizsgált kezelés

    Participants will receive 4 doses of IVIG treatment over 12 weeks.

  • TofacitinibA vizsgált kezelés

    Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Mechanistic Investigation of Therapies for Down Syndrome Regression Disorder
A regiszteradat frissítve
2026. szeptember 3.